PERIOPERATIVE ANESTHESIA: TO DO OR NOT TO DO?

Abstract

Introduction. In patients with chronic loco-motor system diseases the pain often persists after arthroplasty and does not respond to symptomatic therapy.Purpose of study: to evaluate the efficacy of perioperative use of Meloxicam in patients after hip arthroplasty. Patients and methods. The follow-up covered 120 patients (mean age 64.4±5.23 years) after hip arthroplasty. In the main group (n=60) Meloxicam was given 7 days prior to and 3 weeks after surgery; after intervention narcotic analgesic was used on the request. In control group (n=60) the patients were only on narcotic analgesic on request after operation. Treatment results were assessed by 100-millimeter visual analog scale (VAS) and D’Aubigné-Postel Score.Results. Seven days before the surgery the pain severity in the main and control groups was comparable: 85±2.3 and 84±2.1, respectively. In 2 days after operation the pain relief was more pronounced in the main group — 69±2.1 mm versus 82±3.4 mm in the control group (p<0.05). In 3 months those indices made up 10±2.1 and 35±12.6 mm (p<0.001), respectively. In the main group the result was assessed as the excellent and good in 22 patients, in the rest of patients as satisfactory by d’Aubigné-Postel Score. In the control group the good result was recorded in 9, satisfactory — in 47 and poor — in 4 cases.Conclusion. Meloxicam may be considered as an effective perioperative analgesic in large joints arthroplasty.

Keywords

perioperative anesthesia / Meloxicam / arthroplasty / hip joint

References

[1] Бадокин В.В. Место и значение нестероидных противовоспалительных препаратов в терапии остеоартроза. Современная ревматология. 2016; 10 (1): 67-71. doi: 10.14412/1996-7012-2016-1-67-71.

[2] Борисов Д.Б., Киров М.Ю. Эндопротезирование тазобедренного и коленного суставов: эпидемиологические аспекты и влияние на качество жизни. Экология человека. 2013; 8: 52-7.

[3] Тихилов Р.М., Шубняков И.И., Коваленко А.Н. и др. Структура ранних ревизий эндопротезирования тазобедренного сустава. Травматология и ортопедия России. 2014; (2): 5-13. https://doi. org/10.21823/2311-2905-2014-0-2-5-13.

[4] Otten R., van Roermund P.M., Picavet H.S. Trends in the number of knee and hip arthroplasties: considerably more knee and hip prostheses due to osteoarthritis in 2030. Ned. Tijdschr. Geneeskd. 2010; 154: A1534.

[5] Bourne R., Chesworth B., Davis A. et al. Patient satisfaction after total knee arthroplasty: who is satisfied and who is not? Clin. Orthop. Relat. Res. 2010; 468 (1): 57-63. doi: 10.1007/s11999-009-1119-9.

[6] Wylde V., Hewlett S., Learmonth I., Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain. 2011; 152 (3): 566-72.doi: 10.1016/j.pain.2010.11.023.

[7] Фирсов С.А., Белов Г.В., Чухрова М.Г. Хронический болевой синдром в отдаленном послеоперационном периоде и проблема репаративной регенерации при сочетанной травме. Медицина Киргизии. 2017; 1: 43-7.

[8] Clauw D.J. Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s). Best Pract. Res. Clin. Rheumatol. 2015; 29 (1): 6-19. doi: 10.1016/j.berh.2015.04.024.

[9] Борисов Д.Б. Периоперационное обезболивание и кровесберегающие технологии при эндопротезировании крупных суставов: Автореф. дис. ... д-ра мед. наук. СПб; 2014.

[10] D’Aubigné R.M., Postel M. The classic: functional results of hip arthroplasty with acrylic prosthesis. 1954. Clin. Orthop. Relat. Res. 2009; 467 (1): 7-27. doi: 10.1007/ s11999-008-0572-1.

[11] Каратеев А.Е., Насонов Е.Л. Мелоксикам в России: 20 лет вместе. Терапевтический архив. 2016; 12: 159-68. doi: 10.17116/terarkh20168812149-158.

[12] Загородний Н.В., Захарян Н.Г., Пантелеева А.С. и др. Применение Мовалиса в оперативной ортопедии. Фарматека. 2008; 16: 54-7.

[13] Цветкова Е.С., Белоусов Д.Ю., Афанасьева Е.В. Фармакоэкономический анализ применения препарата Мовалис у больных остеоартрозом и ревматоидным артритом. Качественная клиническая практика. 2015; 1: 66-76.

[14] Mastbergen S.C., Biijlsma J.W., Lafeber F.P. Selective COX-2 inhibition is favorable to human early and latestage osteoarthritis cartilage: a human in vitro study. Osteoarthritis Cartilage. 2005; 13 (6): 519-26. doi: 10.1016/j. joca.2005.02.004.

[15] Lapeyre-Mestre M., Grolleau S., Montastruc J. Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006. Fundam. Clin. Pharmacol. 2013; 27 (2): 223-30. doi: 10.1111/j.14728206.2011.00991.x.

RIGHTS & PERMISSIONS

Eco-Vector